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ABSTRACT
Objectives: Primary care high-risk prescribing causes
significant harm, but it is unclear if it is largely driven
by individuals (a ‘bad apple’ problem) or by practices
having higher or lower risk prescribing cultures (a
‘spoiled barrel’ problem). The study aimed to examine
the extent of variation in high-risk prescribing between
individual prescribers and between the practices they
work in.
Design, setting and participants: Multilevel
logistic regression modelling of routine cross-sectional
data from 38 Scottish general practices for 181 010
encounters between 398 general practitioners (GPs)
and 26 539 patients particularly vulnerable to adverse
drug events (ADEs) of non-steroidal anti-inflammatory
drugs (NSAIDs) due to age, comorbidity or co-
prescribing.
Outcome measure: Initiation of a new NSAID
prescription in an encounter between GPs and eligible
patients.
Results: A new high-risk NSAID was initiated in 1953
encounters (1.1% of encounters, 7.4% of patients).
Older patients, those with more vulnerabilities to
NSAID ADEs and those with polypharmacy were less
likely to have a high-risk NSAID initiated, consistent
with GPs generally recognising the risk of NSAIDs in
eligible patients. Male GPs were more likely to initiate a
high-risk NSAID than female GPs (OR 1.73, 95% CI
1.39 to 2.16). After accounting for patient
characteristics, 4.2% (95% CI 2.1 to 8.3) of the
variation in high-risk NSAID prescribing was
attributable to variation between practices, and 14.2%
(95% CI 11.4 to 17.3) to variation between GPs. Three
practices had statistically higher than average high-risk
prescribing, but only 15.7% of GPs with higher than
average high-risk prescribing and 18.5% of patients
receiving such a prescription were in these practices.
Conclusions: There was much more variation in high-
risk prescribing between GPs than between practices,
and only targeting practices with higher than average
rates will miss most high-risk NSAID prescribing.
Primary care prescribing safety improvement should
ideally target all practices, but encourage practices to
consider and act on variation between prescribers in
the practice.
BACKGROUND
Prescribed drugs are the single most com-
monly used medical intervention. They
deliver signiﬁcant individual and population
beneﬁt, but are also a common source of
harm. Approximately 6.5% of emergency
hospital admissions in the UK are caused by
adverse drug events (ADEs),1 2 and ADEs
were the reason for an estimated 4.3 million
Strengths and limitations of this study
▪ The study used data routinely recorded in
general practitioner (GP) electronic medical
records making it possible to examine actual
practice on a large scale, and the data used
came from practices participating in a national
morbidity data set which had all received training
and financial support to maintain particularly
high quality data.
▪ We additionally examined data quality carefully,
and restricted analysis to a topic (non-steroidal
anti-inflammatory drugs (NSAID) prescribing)
and type of prescription (initiation of NSAID pre-
scribing) where we could demonstrate that data
quality was high.
▪ All routine data studies share limitations, notably
the type and quality of the data recorded,
although our choice of practices, topic and type
of prescription makes us confident in the find-
ings of this analysis. However, clinical IT
systems contain minimal data on GP character-
istics and data about practices are restricted to
structural characteristics rather than internal
organisation, which limits the extent to which we
can explain the variation observed.
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ambulatory care consultations and over 100 000 hospital
admissions in the USA in 2005.3 Commonly implicated
drugs include antiplatelet agents such as aspirin, non-
steroidal anti-inﬂammatory drugs (NSAIDs), anticoagu-
lants, blood pressure lowering drugs and hypoglycaemic
drugs,2 with deaths after admission most frequently due
to antiplatelet drugs and NSAIDs.1 A large proportion of
ADEs are preventable, but it is unclear whether risk
varies between individual clinicians and healthcare
settings.4
Many healthcare safety failures are largely attributable to
shortcomings in the environment that individuals work
in.5 It is not surprising that individuals do not wash their
hands if there are no facilities for doing so, and ﬁxing
such system problems is critical. However, even with inter-
ventions to create better systems, hand washing remains
highly variable between individuals.6 In some circum-
stances, the actions of a few individuals is an important
determinant of system performance with, for example, 3%
of Australian doctors accounting for 49% of complaints
that were escalated to regional or federal ombudsmen.7
The appropriate balance between system and individual
intervention to improve safety is therefore likely to depend
on how strongly systems inﬂuence individual action and
whether variation in process or outcome is determined
more at the system or individual level.
There have been a small number of studies of primary
care prescribing which have used robust statistical tech-
niques such as multilevel modelling to examine vari-
ation,4 8–14 but only two of these studies examined
variation at multiple levels of the healthcare system.
Both found that variation between clinics and variation
between individual physicians were important determi-
nants in variation in prescribing for osteoporosis and
adherence to statin guidelines,14 11 suggesting that indi-
vidual action and practice culture both are important
inﬂuences on prescribing. Further evidence that practice
culture matters is provided by an analysis of adherence
to three prescribing guidelines which found that prac-
tices tended to adhere (or not) to guidelines generally
rather than adhering to some but not others, consistent
with prescribers’ decisions to follow prescribing guide-
lines being signiﬁcantly inﬂuenced by the wider ‘thera-
peutic traditions’ in the practice they work in.13
We have previously shown that high-risk prescribing is
common in UK primary care, with an approximately
fourfold variation between practices after accounting for
casemix.4 However, it is unclear whether the observed
variation between practices is mainly due to some prac-
tices having a particularly risky prescriber in them (an
individual clinician or ‘bad apple’ problem) or is
because clinicians in the same practice tend to prescribe
in similar ways (a practice culture or ‘spoiled barrel’
problem). Understanding such variation is important to
inform how best to target safety improvement.15 To the
best of our knowledge, no study has examined how high-
risk prescribing varies between individual prescribers
and practices,16 which is the aim of this analysis.
METHODS
Data set
Data were extracted from 38 Scottish general practices
via the University of Aberdeen Primary Care Clinical
Informatics Unit. We deliberately restricted analysis to
these 38 practices because we considered that high-
quality data recording was required for an analysis at GP
level, and all these practices contributed to an NHS
Scotland national morbidity recording data set and had
therefore received training in, and ﬁnancial support for,
high-quality data recording. Like almost all UK general
practices, these practices all used an electronic medical
record which included data on morbidity (recorded as
Read Codes, which are the universally used coding
system for this purpose in the UK), demography and
prescribing. Patients are only allowed to be registered
with one general practice at a time, and that practice
has responsibility for all community prescribing includ-
ing that recommended by hospital specialists who only
ever directly prescribe a small number of drugs for com-
munity use such as some cytotoxic agents.
We chose to focus on oral NSAID prescribing because
it is a common cause of harm, and because the decision
to initiate NSAIDs is almost completely attributable to
the prescribing GP. This is not the case for many other
high-risk drugs prescribed such as oral methotrexate in
rheumatoid arthritis or antipsychotics in older people
with dementia, where specialists frequently recommend
initiation. Although the GP who acts on that recommen-
dation takes legal responsibility for the prescription,
attribution of the decision to the GP alone is clearly not
straightforward. During initial data exploration, we estab-
lished that the electronic medical record did not record
the name of the doctor printed on ‘repeat’ prescriptions
(those authorised for reissue by receptionists). We there-
fore focused on examining initiation of high-risk oral
NSAID prescriptions, since initial analysis showed that
clinician identiﬁers were reliably recorded in this
context.
Outcome and explanatory variables
The outcome examined was the issuing of a one-off oral
NSAID prescription to an individual particularly vulner-
able to NSAID ADEs who had not had an oral NSAID
prescription in the 12 months before each encounter
examined. Oral NSAIDs were deﬁned as all oral prepara-
tions of drugs listed in British National Formulary
(BNF) chapter 10.1.1 (which does not include
aspirin).17 Patients were deﬁned as particularly vulner-
able to NSAID ADEs at the time of the encounter if one
or more of ﬁve criteria was present: aged 75 years and
older on or before the encounter date; Read Code for
peptic ulcer ever recorded on or before the encounter
date; Read Code for heart failure ever recorded on or
before the encounter date; co-prescribed aspirin or clo-
pidogrel at the time of the encounter; or co-prescribed
an oral anticoagulant at the time of the encounter (war-
farin, acenocoumarol or phenindione which were the
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only available drugs at the time).18 19 To ensure that the
NSAID was truly prescribed to a patient taking a relevant
drug that increased bleeding risk, co-prescription was
deﬁned either as the NSAID being prescribed on the
same day as aspirin, clopidogrel or an oral anticoagu-
lant, or the aspirin, clopidogrel or oral anticoagulant
being prescribed in the 84 days before and the 84 days
after the NSAID prescription. NSAID prescribing for
these individuals was clearly stated as risky and to be
avoided in the March 2005 edition of the British
National Formulary which is the most commonly used
source of drug advice by UK prescribers. We therefore
assumed that the potential risk of NSAID use in such
patients was widely known in the time period
examined.17
An encounter between a patient and a GP was eligible
for analysis if it occurred between 1 January 2006 and 31
December 2006 at a time when the patient was perman-
ently registered with the practice and the patient was
particularly vulnerable to NSAID ADEs at the time of
the encounter and had not had an NSAID prescribed in
the year before the encounter. We chose to use 2006
because that year had the most practices available who
were eligible for the study as described above.
Encounters could be in a range of different contexts,
including face to face in normal surgery, on home visits
or on the telephone. An individual patient could there-
fore only have high-risk NSAID initiation once during
the 1 year study period, and their encounters ceased to
be eligible for inclusion after that NSAID initiation.
Explanatory variables were at the encounter, GP or
patient level. Available data at the encounter level were
the encounter type (normal surgery, telephone consult-
ation or unknown/other), the number of risk factors for
NSAID ADEs that a patient had at the time of the
encounter, whether the patient had a ‘relevant diagnosis’
recorded in the encounter (deﬁned as a Read Code
from chapter N musculoskeletal conditions, chapter
R ill-deﬁned conditions/working diagnoses, chapter
S injuries and poisoning, and chapter 1 history/symp-
toms, used primarily to account for case mix variation
between general practitioners (GPs)). We additionally
ﬁtted variables which were characteristics of the patient
having the encounter including: sex, age, socioeconomic
status (measured by quintiles of postcode derived
Carstairs Score20) and number of active repeat drugs at
the start of 2006 as a measure of overall morbidity and
resource use.
Only two explanatory variables were available at GP
level: GP sex (recorded in the original data) and the
number of encounters each GP had with patients at risk
during the year (calculated from the encounter data
and grouped into quartiles). At practice level, data on
structural characteristics were available, namely the
number of registered patients (listsize, grouped into
quartiles), practice remoteness (three aggregated cat-
egories of the Scottish Executive Urban-Rural
Classiﬁcation—urban, accessible (≤30 min’ drive-time to
an urban area), and remote (≤60 min)), whether or not
the practice was accredited for postgraduate training of
GPs, whether or not the practice was a dispensing prac-
tice, and whether or not the practice holds a General
Medical Services contract (the standard national con-
tract) or a locally speciﬁed contract.
Statistical methods
In the UK, patients are only allowed to be permanently
registered with one practice at a time, but since registra-
tion is with the practice rather than an individual GP,
they can and do see multiple GPs. The outcome being
examined happens in encounters between GPs and
patients, but patients typically encounter several GPs and
GPs encounter many patients. This means that there is
no neat hierarchical clustering of patients with GPs
within practices. We explored using several models of
varying complexity, including models where encounters
were cross-classiﬁed between GPs and patients (GPs have
encounters with multiple patients, and patients have
encounters with multiple GPs, all clustered within prac-
tices), but these more complex models would not con-
verge. Consequently, the analysis presented here is a
three-level hierarchical model of encounters clustered
within GPs clustered within practices, which is an
approximation to the reality but a useful model for this
purpose. Since the outcome is binary (a high-risk NSAID
is either initiated in the encounter or not), multilevel
logistic regression models with random slopes at GP and
practice level were ﬁtted. Assumptions about the normal-
ity of higher level residuals were checked graphically. The
intraclass correlation (ICC) coefﬁcient at GP and practice
level was calculated in the empty model with no explana-
tory variables to estimate the proportion of variation in
outcome that was attributable to variation between GPs
and variation between practices. Encounter level explana-
tory variables were ﬁtted ﬁrst and multilevel univariate
and adjusted ORs of associations between the explana-
tory variables and high-risk NSAID initiation calculated.
Variation between GPs and between practices was then
re-examined after adjusting for differences in encoun-
ter/patient characteristics. GPs and practices with statis-
tically signiﬁcantly higher or lower high-risk NSAID
prescribing were identiﬁed using the GP and practice
level residuals. Median ORs at GP and practice level
were calculated to provide an estimate of variation on
the same scale as the ﬁxed effects ORs.21 The median
OR at GP level can be interpreted as the median differ-
ence in the odds of high-risk NSAID initiation if the
same patient was to randomly encounter two different
GPs in the same practice, and the median OR at practice
level as the median difference in the odds of high-risk
NSAID initiation if the patient was to randomly encoun-
ter two different GPs from different practices. Finally,
associations between GP and practice characteristics and
high-risk prescribing were examined.
Initial data management and analysis was carried out
in SPPS V.21, and multilevel modelling in Stata IC V.11.
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The NHS National Research Ethics Service had previ-
ously approved the anonymous use of these data for
research purposes; therefore, this study did not need
individual ethics approval.
RESULTS
The data set for analysis consisted of 181 010 encounters
in the calendar year 2006 between 26 539 eligible
patients and 398 GPs in 38 practices. Each patient had a
mean of 6.8 (95% CI 6.7 to 6.9) eligible encounters,
and each GP a mean of 455 (95% CI 414 to 496)
encounters with eligible patients. The median age of
included patients was 76 years (IQR 67–82), and 14 062
(53.0%) were women. At the start of the year, the
median number of risk factors per patient for NSAID
ADEs was 1 (range 1–5, IQR 1–2) and the median
number of repeat drugs taken was 4 (range 0–30, IQR
1–6). A total of 239 (60.1%) GPs were male.
During the year of observation, a high-risk NSAID was
initiated in 1953 of the 181 010 eligible encounters
(1.08% of encounters, 95% CI 1.03% to 1.13%). Put
another way, 1953 of 26 539 patients particularly vulner-
able to NSAID ADEs had a high-risk NSAID initiated
(7.4% of patients, 95 CI 7.1% to 7.7%). At practice level,
the high-risk prescribing rate varied from 0.37% to 3.50%
of encounters (median 1.01%, IQR 0.76% to 1.51%), and
at GP level the rate varied from 0 to 20.0% of encounters
(median 0.68%, IQR 0% to 1.50%). Figure 1 shows how
the actual practice rates and individual GP rates varied.
There is a visual impression of substantial variation
between practices and between GPs in the same practice,
although it is noteworthy that 133 (33.4%) GPs had no
high-risk NSAID prescribing in the year examined.
Table 1 shows associations between encounter/patient
and GP characteristics and high-risk NSAID initiation. In
the adjusted model, the most strongly associated variable
was whether or not a relevant diagnosis had been
recorded for the encounter (OR 7.03, 95% CI 6.32 to
7.82). Compared to normal surgery encounters, high-risk
NSAID initiation was less common in telephone encoun-
ters (OR 0.68, 95% CI 0.52 to 0.89) and other/unknown
encounters (OR 0.34, 95% CI 0.29 to 0.42). High-risk
NSAID initiation was less likely with increasing numbers
of risk factors for NSAID associated ADEs (OR 0.61. 95%
CI 0.49 to 0.76, in those eligible for ≥3 indicators vs
those eligible for one). Initiation was less common in the
oldest two groups compared to the youngest (80 years
and over vs under 50 years OR 0.59, 95% CI 0.49 to
0.72). Encounters with people taking 11 or more repeats
had half the odds of resulting in high-risk NSAID initi-
ation than those with people with no active repeat drugs
(OR 0.51, 95% CI 0.39 to 0.68). Male GPs were more
likely to initiate a high-risk NSAID (OR 1.73, 95% CI
1.39 to 2.16, for male GPs compared to female GPs).
The practice level, ICC in the empty model was 0.055
(95% CI 0.029 to 0.102) compared to 0.042 (95% CI
Figure 1 Variation in high-risk NSAID initiation between practices (large circles) and between GPs within practices (small
diamonds) (133 GPs have zero rates, so these and some other plotted GP points overlap). NSAIDs, non-steroidal
anti-inflammatory drugs; GP, general practitioners.
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0.021 to 0.083) in the model adjusted for patient/
encounter level variables (table 2). The GP level ICC in
the empty model was 0.166 (95% CI 0.135 to 0.197)
compared to 0.142 (95% CI 0.114 to 0.173) in the
model adjusted for patient/encounter level variables.
After adjustment for patient/encounter characteristics,
approximately three times more variation in high-risk
NSAID initiation was attributable to variation between
GPs (14.2%) than variation between practices (4.2%).
The median OR at GP level was 2.22 (95% CI 2.00 to
2.50) in the empty model and accounting for patient
and encounter characteristics reduced it slightly to 2.06
(95% CI 1.87 to 2.30), while the median OR at practice
level was 2.52 (95% CI 2.15 to 3.09) in the empty model
and accounting for patient and encounter characteristics
reduced it to 2.28 (95% CI 1.98 to 2.76). On average,
the likelihood of high-risk NSAID initiation therefore
varied approximately twofold if a patient was to ran-
domly encounter two different GPs in the same practice,
and only slightly more if a patient was to randomly
encounter two GPs working in different practices, again
indicating that the greatest variation is between GPs.
After adjustment for patient and encounter character-
istics, 3 of the 38 (7.9%) practices had statistically signiﬁ-
cantly higher than average rates of high-risk NSAID
initiation, and 2 (5.3%) had statistically signiﬁcantly
lower rates. At GP level, 51 (12.8%) of 398 GPs had stat-
istically signiﬁcantly higher than average high-risk
NSAID initiation, and 10 (2.5%) had statistically signiﬁ-
cantly lower rates. Figure 2 shows how these practices
and GPs were distributed. GPs with higher or lower than
average rates of high-risk NSAID initiation were distribu-
ted across the entire range of practices. Only 8/51
(15.7%) GPs with statistically signiﬁcantly higher than
average prescribing were in the three practices with stat-
istically signiﬁcantly higher than average prescribing,
and only 369 (18.9%) of the high-risk NSAID initiations
were in these three practices.
DISCUSSION
High-risk NSAID initiation in patients at particularly
high risk of NSAID related ADEs occurred in 1.1% of
eligible encounters in 2006. In the full multilevel model,
Table 1 Multilevel adjusted associations (only statistically significantly associated variables shown*)
Encounter and GP characteristics
(number of encounters)
n=181 010 encounters, 398 GPs, 38 practices
% (95% CI) of encounters
with high-risk NSAID
initiation
Multilevel univariate
OR (95% CI)
Multilevel adjusted
OR (95% CI)
Encounter type
Normal surgery (n=133 614) 1.33 (1.27 to 1.40) 1 1
Telephone (n=16 855) 0.46 (0.27 to 0.45) 0.26 (0.20 to 0.33) 0.68 (0.52 to 0.89)
Unknown/other (n=30 541) 0.36 (0.30 to 0.44) 0.31 (0.25 to 0.37) 0.34 (0.29 to 0.42)
Indicators triggered at encounter date
1 (n=99 389) 1.38 (1.30 to 1.46) 1 1
2 (n=61 404) 0.79 (0.72 to 0.86) 0.58 (0.52 to 0.64) 0.81 (0.73 to 0.91)
≥3 (n=20 217) 0.48 (0.38 to 0.58) 0.35 (0.28 to 0.42) 0.61 (0.49 to 0.76)
Relevant diagnosis at encounter
No (n=127 984) 0.40 (0.37 to 0.44) 1 1
Yes (n=53 026) 2.72 (2.56 to 2.86) 7.12 (6.48 to 7.97) 7.03 (6.32 to 7.82)
Patient age
<50 years (n=8893) 2.18 (1.85 to 2.51) 1 1
50–59 years (n=10 600) 1.98 (1.70 to 2.26) 0.97 (0.79 to 1.18) 1.07 (0.87 to 1.32)
60–69 years (n=30 991) 1.41 (1.28 to 1.55) 0.68 (0.57 to 0.81) 0.93 (0.77 to 1.12)
70–79 years (n=64 502) 1.05 (0.96 to 1.13) 0.49 (0.42 to 0.58) 0.74 (0.62 to 0.89)
80+ years (n=66 024) 0.66 (0.60 to 0.72) 0.31 (0.26 to 0.37) 0.59 (0.49 to 0.72)
No of repeat drugs
0 (n=24 051) 1.76 (1.58 to 1.94) 1 1
1–2 (n=31 435) 1.39 (1.25 to 1.52) 0.74 (0.64 to 0.85) 0.86 (0.74 to 0.99)
3–4 (n=42 589) 0.85 (0.75 to 0.95) 0.58 (0.50 to 0.66) 0.73 (0.63 to 0.84)
5–6 (n=36 075) 0.77 (0.65 to 0.88) 0.46 (0.40 to 0.54) 0.61 (0.52 to 0.72)
7–8 (n=23 926) 0.77 (0.65 to 0.88) 0.38 (0.35 to 0.50) 0.61 (0.50 to 0.73)
9–10 (n=12 897) 0.70 (0.55 to 0.85) 0.38 (0.30 to 0.48) 0.55 (0.43 to 0.71)
11+ (n=10 037) 0.62 (0.46 to 0.78) 0.32 (0.24 to 0.42) 0.51 (0.39 to 0.68)
GP sex
Women (n=159 GPs, 67 615 encounters) 0.68 (0.53 to 0.83) 1 1
Men (n=239 GPs, 113 395 encounters) 1.32 (1.17 to 1.46) 1.82 (1.44 to 2.31) 1.73 (1.39 to 2.16)
*Patient sex, deprivation, GP number of encounters, and all practice variables (list size, rurality, contract type, training status, dispensing) were
examined but were not significantly associated and therefore not included.
GP, general practitioners; NSAIDs, non-steroidal anti-inflammatory drugs.
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high-risk NSAID prescribing was more likely to occur in
normal surgery encounters and less likely to occur in
encounters with patients with more risk factors for
NSAID adverse drug effects, in encounters with older
patients, and in encounters with patients prescribed
more repeat drugs. These ﬁndings suggest that GPs gen-
erally perceived the NSAID prescribing examined to be
risky because they were on average less likely to
prescribe in people at higher risk of NSAID related
ADEs. At GP level, male prescribers were more likely to
initiate a high-risk NSAID than female GPs (OR 1.73)
even after adjustment for casemix. None of the practice
structural characteristics examined were associated with
high-risk prescribing.
After accounting for encounter and patient character-
istics, 4.2% of the variation in high-risk NSAID
Table 2 Variation between practices and between GPs before and after inclusion of patient and GP characteristics*
Intraclass correlation
coefficient ICC (95% CI) Median OR (95% CI)†
Empty model (no patient or GP characteristics included)
Practice level 0.055 (0.029 to 0.102) 2.52 (2.15 to 3.09)
GP level 0.166 (0.135 to 0.197) 2.22 (2.00 to 2.50)
Patient model (only patient characteristics included)
Practice level 0.042 (0.021 to 0.083) 2.28 (1.98 to 2.76)
GP level 0.142 (0.114 to 0.173) 2.06 (1.87 to 2.30)
Full model (patient and GP characteristics included)
Practice level 0.031 (0.014 to 0.068) 2.14 (1.88 to 2.57)
GP level 0.131 (0.103 to 0.161) 1.98 (1.80 to 2.21)
*Included characteristics are those listed in table 1. Patient sex, deprivation, GP number of encounters, and all practice variables (list size,
rurality, contract type, training status, dispensing) were examined but were not significantly associated and therefore not included.
†The median OR at GP level can be interpreted as the median difference in the odds of high-risk NSAID initiation if the same patient were to
randomly encounter two different GPs in the same practice. The median OR at practice level can be interpreted as the median difference in
the odds of high-risk NSAID initiation if the patient were to randomly encounter two different GPs from different practices (but should be
interpreted in terms of how different it is from the median OR at GP level since it includes variation between GPs as well as between
practices. GP, general practitioners; ICC, intraclass correlation; NSAIDs, non-steroidal anti-inflammatory drugs.
Figure 2 Variation in high-risk NSAID initiation between practices (large circles) and between GPs within practices (small
diamonds). (On the basis of the multilevel model after accounting for encounter and patient characteristics, green indicates GP or
practice is statistically lower than average, red indicates GP or practice is statistically higher than average. 133 GPs have zero rates,
so these and some other plotted GP points overlap). NSAIDs, non-steroidal anti-inflammatory drugs; GP, general practitioners.
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prescribing was attributable to variation between prac-
tices (similar to between-practice variation found in
other studies16), and 14.2% to variation between GPs (at
the upper end of between-physician variation found in
other studies16). Variation between GPs was of similar
magnitude to most of the individual characteristics (such
as patient age and sex) examined, in that the odds of
NSAID initiation in a patient randomly encountering
two different GPs in the same practice varied twofold on
average simply by virtue of seeing different GPs.
A strength of the study is that the use of data routinely
recorded in GP electronic medical records makes it pos-
sible to examine actual practice on a large scale, but all
such studies share limitations, notably the type and
quality of the data recorded. In terms of type of data, we
had virtually no information about the GPs except their
sex, because nothing else is routinely recorded in clin-
ical IT systems, and only limited information about prac-
tice structure but not internal organisation. Data quality
depends on how practices use their clinical IT system,
although all the practices in this analysis contributed to
a national morbidity data set and had received training
and ﬁnancial support to maintain high quality data.
However, the use of such practices does potentially limit
the generalisability of the ﬁndings since we do not know
how their prescribing compares with other practices.
Finally, several NSAIDs are available from pharmacists to
buy over the counter which cannot be accounted for in
GP data, although neither GPs nor practices are directly
responsible for such use. We therefore believe that this
analysis of high-risk NSAID initiation is valid (although
extending to repeat prescriptions is not possible with
current UK data, and extending to other drugs would
have to account for the difﬁculties of attributing the
decision to initiate which will sometimes be made by a
specialist). The study is therefore better at quantifying
the extent of variation (which was the primary objective
of our study) than explaining the variation observed.
For example, we do not know whether some GPs were
not aware of the risks (a knowledge problem potentially
amenable to relatively simple educational interventions)
or had higher risk tolerance (which might be associated
with GP sex, eg, but where more intensive interventions
would most likely be needed to change behaviour).
Studies of variation at multiple levels of healthcare
systems are relatively rare, with only 12 identiﬁed by a
recent systematic review of 39 studies using multilevel
modelling or other appropriate techniques to examine
variation.16 In these studies, variation between physicians
was usually greater than variation between the institutions
or areas that those physicians worked in. However, pat-
terns of variation appear to depend on the extent to
which the outcome examined is directly controlled by
individual doctors or more reliant on the organisation of
care by the practices or hospitals those doctors work in.
For example, in a study examining diabetes care,
between-physician variation in blood pressure measure-
ment was larger than between-hospital variation, whereas
between-hospital variation in eye screening was larger
than between-physician variation.22 Roberts et al23 ele-
gantly show that variation in patient satisfaction for out-
comes controlled by the practice, such as cleanliness or
building access, was largely at practice level, whereas vari-
ation for consultation outcomes such as communication
was much larger at GP level. The authors observed that
practices with high overall satisfaction rates rarely or
never had a low performing GP in them, and that prac-
tice satisfaction could therefore be used as a screening
tool to identify practices where measurement at GP level
would be helpful. In contrast, our study found that GPs
with signiﬁcantly higher and lower rates of high-risk
NSAID initiation were distributed across the entire range
of practice rates, and focusing only on higher risk prac-
tices would miss most higher risk GPs and most high-risk
prescribing.
Key implications are that measurement of high-risk pre-
scribing at GP level is not routinely feasible using electronic
data in the UK because electronic data do not reliably
record who signed the paper prescription, which is a par-
ticular issue for ‘repeat’ prescriptions authorised for
regular reissue. For new prescriptions, electronic data are
reasonably reliable, but attribution may still be problematic
because, although the GP who signs the prescription takes
legal responsibility for it, many drugs are initiated on spe-
cialist recommendation. Measurement at practice level can
identify practices with higher than average prescribing, but
most (84.3%) GPs with signiﬁcantly raised high-risk pre-
scribing and most (81.5%) patients initiated on a high-risk
prescription are not in these practices. Although some
practices with particularly high rates of high-risk prescrib-
ing may need individual support, primary care prescribing
safety improvement will therefore most likely have to
target all practices. This could take the form of regular
feedback of practice rates with facilitation of review of
patients receiving high-risk prescribing and examination by
the practice of internal variation between GPs to inform an
appropriate practice response.24 Routine measurement at
GP level will require universal adoption of true electronic
prescribing where the ‘signing’ of the prescription is done
with a unique identiﬁer, such as the General Medical
Council registration number in the UK.
Finally, although this study has quantiﬁed variation in
high-risk prescribing between practices and between
GPs, the data available do not allow much exploration of
factors explaining such variation. The only GP or prac-
tice characteristic associated with high-risk prescribing
was GP sex, with male GPs being more likely to initiate a
high-risk NSAID than female GPs, but whether this
relates to a different casemix beyond what could be con-
trolled for in this study, or greater knowledge gaps about
the risk and beneﬁt of drugs, or greater tolerance of risk
by men is uncertain. Research is needed to better under-
stand such factors and how these inﬂuence prescribing
decisions. For example, although high-risk NSAID initi-
ation was less common in people with multiple risk
factors for NSAID ADEs implying that GPs were
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generally aware of increasing risk, actually understand-
ing how risk and beneﬁt are balanced in decision-
making using appropriate qualitative (eg, observation
and ‘think-aloud’ interviewing) or quantitative (eg, dis-
crete choice experiments) methods would be very
useful. Similarly, it is unclear whether practices or GPs
have a general tendency to be high-risk prescribers
across multiple measures or whether most practices have
one or more areas where they are different from
average. Finally, there are relatively few studies of inter-
ventions to reduce primary care high-risk prescribing,
with the best evidence to date for pharmacist-led inter-
ventions,25 26 although other studies of GP-led interven-
tions are in progress.27 28 Returning to the original
question, the ﬁndings suggest that high-risk prescribing
is more of a ‘bad apple’ than a ‘spoiled barrel’ problem,
but improvement is likely to require the whole crop of
prescribers to take professional responsibility for high-
risk prescribing in their practice and to work collabora-
tively to minimise preventable harm from drug therapy.
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